Hearing that immunotherapy is no longer controlling your cancer can feel like someone suddenly changed the rules halfway through the game. The treatment may have shrunk tumors, kept the disease stable, or offered hope after other options failed. Then a scan shows growth, symptoms worsen, or your oncologist uses the word nobody wanted to hear: progression.
Although this news is serious, it does not automatically mean that nothing else can be done. The next step may involve confirming that the cancer is truly progressing, learning why the treatment stopped working, testing the tumor again, switching therapies, treating a troublesome area directly, joining a clinical trial, or focusing more heavily on comfort and quality of life.
The right choice depends on your cancer type, where it has spread, previous treatments, tumor biomarkers, overall health, symptoms, and personal goals. In other words, there is no universal “Plan B” hiding in an oncology filing cabinet. Your next plan should be built specifically for you.
Why Does Immunotherapy Stop Working?
Immunotherapy helps the immune system recognize, attack, or control cancer cells. Immune checkpoint inhibitors, for example, block signals that cancer uses to switch off immune cells. Other forms of immunotherapy include CAR T-cell therapy, cancer vaccines, immune modulators, and certain monoclonal antibodies.
Some cancers never respond to immunotherapy. This is called primary resistance. Other tumors initially shrink or stabilize but later begin growing again, which is known as acquired resistance. Cancer cells can change genetically, stop displaying recognizable targets, block immune signals, prevent T cells from entering the tumor, or create a tumor environment that suppresses immune activity.
None of this means you failed the treatment. You did not eat the wrong breakfast, think insufficiently positive thoughts, or somehow “let” the cancer return. Treatment resistance is driven by cancer biology, and unfortunately, cancer cells can be remarkably talented at adapting.
First, Confirm What “Stopped Working” Actually Means
Before choosing a new treatment, ask your oncologist to explain exactly what has changed. “Immunotherapy stopped working” can describe several different situations:
- The cancer is growing in several locations.
- Only one or two tumors are growing while the rest remain controlled.
- New lesions have appeared on imaging.
- Symptoms or laboratory results suggest progression.
- The treatment was stopped because of serious side effects rather than tumor growth.
- A planned course of treatment has ended, but the cancer remains controlled.
These situations may lead to very different decisions. Widespread progression often requires a new systemic therapy, while limited progression may sometimes be treated locally with radiation, surgery, or another procedure.
Could the Scan Show Pseudoprogression?
In uncommon cases, tumors treated with immunotherapy temporarily look larger because immune cells and inflammation have entered the area. New spots may also appear before later scans show improvement. This phenomenon is called pseudoprogression. It has been documented with immunotherapy, but it is much less common than true cancer progression.
Your doctor may compare multiple scans, evaluate your symptoms, review laboratory tests, order different imaging, or recommend a repeat scan after an appropriate interval. Occasionally, a biopsy is needed. Continuing ineffective treatment can allow cancer to advance, so pseudoprogression should be considered carefully rather than treated as the default explanation for every disappointing scan.
Ask Whether the Cancer Should Be Tested Again
Cancer can evolve during treatment. A tumor sample collected at diagnosis may not perfectly represent the cancer months or years later. A repeat tissue biopsy or liquid biopsy may reveal new biomarkers, mutations, proteins, or pathways that influence the next treatment choice.
Biomarker testing may identify an approved targeted therapy, a treatment based on a tumor feature rather than its original location, or a clinical trial designed for cancers with a particular molecular change. Testing is not useful in every case, and it does not always find an actionable target, but it is worth asking about when the disease has progressed.
Useful questions include:
- Should my original biopsy be tested for additional biomarkers?
- Would a new biopsy provide better information?
- Is a liquid biopsy appropriate for my cancer?
- Could the results qualify me for targeted treatment or a clinical trial?
- Has my diagnosis or cancer subtype been reviewed by a specialist pathologist?
Discuss the Next Standard Treatment Options
The best treatment after immunotherapy depends heavily on the cancer involved. A strategy that makes sense for melanoma may be completely wrong for lung, kidney, bladder, breast, or colorectal cancer. Your oncologist should explain which options are supported by evidence for your exact diagnosis and treatment history.
Switching to Chemotherapy
Chemotherapy may still work even if immunotherapy has failed. Different chemotherapy drugs attack cancer through mechanisms unrelated to immune checkpoints. The specific drug or combination will depend on what you have already received, how long it worked, your current organ function, and the side effects you are willing to accept.
In selected cancers, researchers have also studied whether chemotherapy given after an immune checkpoint inhibitor behaves differently because of lingering changes in the immune environment. However, this possibility is cancer-specific and should not be interpreted as a guarantee that chemotherapy will work better after immunotherapy.
Targeted Therapy or Hormone Therapy
If testing identifies a treatable molecular target, targeted therapy may block a protein or pathway the cancer depends on. Examples can include alterations involving EGFR, ALK, BRAF, HER2, RET, NTRK, BRCA-related pathways, or other cancer-specific targets. Hormone therapy may remain an option for cancers driven by estrogen, progesterone, or androgen signaling.
Targeted treatments are not interchangeable, and a mutation with a similar name does not always have the same meaning across cancer types. Treatment selection should be based on validated testing and current cancer-specific guidelines.
Another Immunotherapy Strategy
Switching from one immunotherapy drug to another is not automatically helpful because drugs targeting the same immune pathway may face the same resistance mechanism. Still, selected patients may be candidates for a different immune combination, a checkpoint inhibitor paired with chemotherapy or targeted therapy, cellular therapy, a cancer vaccine, or another investigational immune treatment.
Combination approaches can sometimes produce stronger antitumor effects than either treatment alone, but they may also cause more side effects. Whether a combination is appropriate depends on the cancer, prior therapy, biomarkers, and available clinical evidence.
Radiation, Surgery, or Local Procedures
If only a small number of tumors are growinga situation sometimes called oligoprogressionyour team may consider treating those areas directly while reassessing the broader systemic plan. Options may include surgery, stereotactic radiation, ablation, embolization, or other procedures.
Radiation can relieve pain, bleeding, pressure, breathing problems, or neurologic symptoms caused by a tumor. Researchers are also studying how radiation may interact with the immune system and whether it can help overcome resistance in selected patients. This remains highly dependent on cancer type and clinical circumstances.
Consider a Clinical Trial Early
A clinical trial may offer access to a new drug, treatment combination, cellular therapy, vaccine, targeted agent, or biomarker-driven strategy. Trials are not reserved only for people who have exhausted every possible treatment. In many cases, exploring trials earlier gives patients more choices because eligibility can depend on prior therapies, organ function, performance status, and the number of treatments already received.
Early-phase trials primarily study safety and dosing, although modern phase 1 cancer trials increasingly use molecular selection and may offer clinical benefit to some participants. Later-phase trials compare promising strategies with existing standards of care. A trial can provide an opportunity, but it cannot promise that an experimental treatment will work.
Ask your oncologist:
- Are there trials for my cancer type and treatment history?
- Are there trials based on my biomarkers rather than the tumor’s location?
- Would joining require travel or temporary relocation?
- Which expenses are covered by the trial, my insurance, or neither?
- What are the possible benefits, risks, and time commitments?
- What standard treatment would I receive if I did not enroll?
Get a Second Opinion
A second opinion can be especially valuable when immunotherapy stops working, when the cancer is rare, or when several reasonable options exist. Another oncologist may confirm the current plan, suggest additional testing, identify a trial, or explain why a proposed treatment is unlikely to help.
Seeking another opinion is not an act of betrayal. Good oncologists generally understand that complex decisions deserve careful review. Consider consulting a specialist at an NCI-designated cancer center, academic medical center, or program that treats a high volume of your cancer subtype.
Bring pathology reports, imaging files, scan reports, biomarker results, treatment dates, medication doses, records of side effects, and a summary of how the cancer responded. A beautifully organized folder will not defeat cancer, sadly, but it can prevent an expensive appointment from becoming a scavenger hunt.
Compare Benefits With Burdens
Not every available treatment is automatically a good treatment. Ask what the next therapy is realistically expected to accomplish. Is the goal to cure the cancer, shrink it, delay growth, relieve symptoms, or possibly extend life? How likely is that outcome, and what side effects or hospital visits might be required?
When several treatments have stopped controlling the disease, it becomes increasingly important to compare the possible benefit of another therapy with its physical, emotional, and financial burdens. Choosing not to pursue another cancer-directed treatment is a legitimate medical decision, not surrender or a lack of courage.
Add Palliative CareEven If You Continue Treatment
Palliative care focuses on symptom relief, emotional support, communication, and quality of life. It can be provided alongside chemotherapy, radiation, targeted therapy, immunotherapy, or clinical-trial treatment. It is not limited to the final days of life and is not the same thing as hospice.
A palliative care team may help manage pain, fatigue, nausea, appetite changes, shortness of breath, sleep problems, anxiety, depression, caregiver stress, and difficult family conversations. The team can also help clarify treatment goals when medical choices feel overwhelming.
Hospice is different. It is generally considered when cancer-directed treatment is no longer helping or is no longer wanted and the focus shifts primarily to comfort. Asking about hospice does not force you to enroll. It simply gives you information before a crisis makes every decision harder.
Questions to Bring to Your Next Oncology Appointment
- How certain are we that the cancer is truly progressing?
- Is the progression widespread or limited to a few areas?
- Could inflammation, treatment effects, or pseudoprogression affect the scan?
- Would another biopsy or biomarker test change my options?
- What standard treatments remain available?
- Could surgery or radiation treat the growing areas?
- Which clinical trials fit my diagnosis and previous treatments?
- What is the main goal of the recommended treatment?
- How likely is it to help, and for approximately how long?
- What side effects, costs, travel, and time commitments should I expect?
- What might happen if I delay treatment or choose supportive care alone?
- Should I obtain a second opinion before deciding?
A Patient-Experience Perspective: Living Through the Change in Plans
The following is a composite perspective based on common concerns reported by patients and caregivers, not the story of one identifiable person.
At first, immunotherapy can feel different from other cancer treatments. There may be cautious optimism around every infusion and scan. Family members begin treating imaging appointments like championship games: everyone is nervous, nobody sleeps properly, and at least one person sends an overly cheerful message filled with exclamation points.
When the treatment works, even temporarily, life may begin to expand again. A patient may make travel plans, return to work, attend a wedding, or simply enjoy weeks in which cancer is not the first thought every morning. That period matters. It is not erased because the cancer eventually progresses.
Then comes the difficult appointment. The oncologist turns the computer screen, points to several areas, and explains that the tumors are growing. Patients often remember only fragments of what follows. Words such as “second-line treatment,” “biopsy,” and “clinical trial” may float through the room while the mind gets stuck on one sentence: It is no longer working.
A helpful response is to avoid forcing an immediate decision unless there is a genuine medical emergency. Patients can ask for a written summary, record the conversation when permitted, bring a trusted person, and schedule another discussion after the initial shock has settled. A caregiver can take notes while the patient concentrates on listening and asking questions.
The next few days may bring an exhausting combination of research and uncertainty. Online searches can produce miracle claims, frightening statistics, and enough acronyms to make alphabet soup look underqualified. Reliable information from the oncology team, major cancer organizations, and experienced cancer centers is more useful than anonymous promises that one supplement “starves tumors by Tuesday.”
Many patients also struggle with guilt. They may wonder whether stress, food, exercise, missed sleep, or a moment of pessimism caused the treatment to fail. Loved ones may unintentionally make this worse by insisting that the patient must “keep fighting” or “stay positive.” Emotional hope can be valuable, but it is not a medication, and sadness does not feed cancer.
A more practical form of hope is flexible. It may mean hoping the next treatment shrinks the disease. It may mean hoping a clinical trial becomes available, radiation relieves pain, or a family milestone can still be reached. Sometimes hope means protecting energy for meaningful days rather than spending every remaining hour in clinics.
Patients often find it useful to identify two sets of priorities. The first concerns cancer control: living longer, reducing tumor burden, preventing complications, or preserving future treatment options. The second concerns daily life: remaining independent, thinking clearly, avoiding hospitalization, spending time at home, attending an important event, or controlling pain. A good plan should consider both lists.
Support groups, oncology social workers, counselors, spiritual-care professionals, and patient navigators can help with the emotional and logistical load. Peer communities can reduce isolation, provided medical claims are checked with the care team.
There may be no perfect choice. One patient may accept difficult side effects for a small chance of additional tumor control. Another may decide that comfort, travel, family time, or freedom from hospital visits matters more. Both decisions can be thoughtful and brave.
The most important experience-related lesson is that progression is not a personal failure. It is new medical information. That information may be painful, but it can still be used to build a clearer planone based on evidence, honest expectations, and what makes life worth living to the person at the center of the conversation.
Conclusion
When immunotherapy stops working, begin by confirming what the scans and symptoms truly show. Ask whether repeat pathology review, biomarker testing, a new biopsy, local treatment, chemotherapy, targeted therapy, another immune strategy, or a clinical trial could be appropriate. A second opinion can help you understand the full range of choices.
At the same time, discuss symptom management and palliative care early. The goal is not merely to find another treatment at any cost. It is to choose a plan whose possible benefits make sense in relation to its burdens and whose goals reflect what matters most to you.
Cancer may change the route without asking permission. You still deserve clear information, compassionate support, and a meaningful voice in deciding where the road goes next.
